Results 111 to 120 of about 219,164 (263)

Treatment‐Related Adverse Events and Health‐Related Quality of Life Associated With Immune Checkpoint Inhibitor Treatment for Mucosal Head and Neck Squamous Cell Carcinoma: A Scoping Review

open access: yesHead &Neck, EarlyView.
ABSTRACT Background Supportive care needs of patients receiving immune checkpoint inhibitors (ICIs) for head and neck squamous cell carcinoma (HNSCC) are ill‐defined. Hence, known treatment‐related adverse events (TRAEs) and health‐related quality of life (HRQoL) associated with ICI treatment for HNSCC were examined to inform future supportive care ...
N. D. O'Donnell   +11 more
wiley   +1 more source

Woman With Dyspnea

open access: yesAnnals of Emergency Medicine, 2023
openaire   +2 more sources

Head and Neck Lymph Node Metastases From Cancer of Unknown Primary: Outcomes From p16‐Guided Mucosal Radiotherapy

open access: yesHead &Neck, EarlyView.
ABSTRACT Background The AJCC 8th edition distinguishes p16‐positive oropharyngeal head and neck carcinoma of unknown primary (HNCUP) due to its superior prognosis. However, standardized radiation volume guidelines are lacking. This study evaluates the safety of p16‐guided mucosal volume reduction.
Philippe Harris   +16 more
wiley   +1 more source

Development and Preliminary Validation of a Modified Thyroid Symptom Questionnaire (TSQ)

open access: yesHead &Neck, EarlyView.
ABSTRACT Background This study aimed to modify and validate the Thyroidectomy Voice and Symptom Questionnaire (TVSQ) to serve as a symptom screening tool in benign thyroid disease. Methods A 32‐item modified TVSQ was developed and administered alongside a symptom checklist to outpatients; controls were recruited to determine discriminative validity ...
Vikash Yogaraj   +2 more
wiley   +1 more source

Patient‐Reported Outcomes with Selpercatinib Among Patients with RET Fusion–Positive Non‐Small Cell Lung Cancer in the Phase I/II LIBRETTO‐001 Trial

open access: yesThe Oncologist, EarlyView., 2021
Abstract Background LIBRETTO‐001 is an ongoing, global, open‐label, phase I/II study of selpercatinib in patients with advanced or metastatic solid tumors. We report interim patient‐reported outcomes in patients with RET fusion–positive non‐small cell lung cancer (NSCLC).
Anna Minchom   +11 more
wiley   +1 more source

Dyspnea as a marker of prognosis in immunocompromised patients with acute respiratory failure. [PDF]

open access: yesAnn Intensive Care
Demoule A   +28 more
europepmc   +1 more source

Validation of the fullPIERS model for predicting severe maternal outcomes in preeclampsia in five Brazilian centers

open access: yesInternational Journal of Gynecology &Obstetrics, EarlyView.
Abstract Objective The objective of this study is to validate the fullPIERS (Pre‐eclampsia Integrated Estimate of Risk) prognostic model in a large, multicenter cohort of Brazilian women with preeclampsia and to determine the optimal cutoff for clinical application in the Brazilian context.
Pedro do Valle Teichmann   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy